🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites📍 Baden-Baden📍 Heidenheim📍 Schwäbisch Hall Novartis Pharmaceuticals HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Edetate Calcium Disodium, Multivitamin, Succimer A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites📍 Birmingham📍 Stockton📍 Torrance Novartis Pharmaceuticals · Tests: TKIs Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia NCT06082804NA1 site📍 Avignon Centre Hospitalier Henri Duffaut - Avignon · Tests: APN and medical management, Medical management, Quality of life assessment, Treatment compliance assessment Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia NCT02115295Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients NCT06453902Phase 21 site📍 Beijing Shenzhen TargetRx Co., Ltd. · Tests: TGRX-678 Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. NCT06514534Phase 26 sites📍 Bordeaux📍 Lille📍 Lyon Novartis Pharmaceuticals · Tests: ABL001/Asciminib ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites📍 Akita📍 Sapporo📍 Suita-shi Enliven Therapeutics · Tests: ELVN-001 Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment NCT07651878Phase 11 site📍 Bergen Mendus · Tests: vididencel TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients NCT06088888Phase 12 sites📍 Houston📍 Seattle Shenzhen TargetRx Co., Ltd. · Tests: TGRX-678 Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers NCT03589729Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Dexrazoxane Hydrochloride, Gemtuzumab Ozogamicin, Idarubicin Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP NCT07354074Phase 234 sites📍 New Brunswick📍 New York📍 Cincinnati Novartis Pharmaceuticals · Tests: Asciminib single agent A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant NCT07020533Phase 13 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Letermovir,… Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib NCT01746836Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation NCT04838041Phase 25 sites📍 Detroit📍 Buffalo📍 New York Medical College of Wisconsin · Tests: Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) NCT06684964n/a4 sites📍 Dammam📍 Jeddah📍 Riyadh Novartis Pharmaceuticals · Tests: asciminib A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia NCT05304377Phase 145 sites📍 New York📍 The Bronx📍 Portland Enliven Therapeutics · Tests: ELVN-001 Asciminib Roll-over Study NCT04877522Phase 485 sites📍 Ann Arbor📍 New York📍 Portland Novartis Pharmaceuticals · Tests: Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) NCT06163430Phase 1, Phase 254 sites📍 Birmingham📍 Gilbert📍 Orange Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New… · Tests: MK-4208 Methods of T Cell Depletion Trial (MoTD) NCT04888741Phase 217 sites📍 Cardiff📍 Birmingham📍 Bristol University of Birmingham · Tests: Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, Mycophenolate Mofetil CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant NCT06059391Phase 23 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hema… Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia NCT06229860n/a1 site📍 Orange University of California, Irvine · Tests: Interview Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML NCT06409936Phase 211 sites📍 Barcelona📍 Bilbao📍 Girona Gruppo Italiano Malattie EMatologiche dell'Adulto · Tests: Asciminib, Nilotinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy